# Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer

> **NCT04024800** · PHASE2 · UNKNOWN · sponsor: **NuGenerex Immuno-Oncology** · enrollment: 29 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **BIOLOGICAL:** AE37 Peptide vaccine
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT04024800
- **Lead sponsor:** NuGenerex Immuno-Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-05-03
- **Primary completion:** 2023-06-30
- **Final completion:** 2024-06-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2021-06-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04024800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04024800, "Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04024800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*